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Results: Of 634 patients, 387 (61%) underwent PCI. The rates of overall and major
bleeding were 68% and 18% (25% reversal), 39% and 12% (50% reversal), 35% and
9% (75% reversal), and 34% and 7% (100% reversal) compared with 38% and 11%
(heparin). Ischemic events were numerically less frequent in REG1 patients vs. heparin
(4.4% versus 7.3%, p=0.3). Urgent TVR was rare (1%) in both REG1 and heparin
groups.
Conclusion: High level factor IX inhibition coupled with at least 50% reversal of
pegnivacogin activity may represent an attractive strategy in ACS patients undergoing
PCI and deserves testing in adequately powered phase 3 clinical trials.
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Background: Bivalirudin (BIV) has been shown to reduce bleeding complications
compared to unfractionated heparin (UFH) after coronary intervention. The
“Preclosure” technique with a suture-based closure device (VCD) has been reported
to achieve hemostasis after procedures with large caliber arterial sheaths. Clinical
outcomes with BIV, UFH and VCD in balloon aortic valvuloplasty (BAV) have not
been reported.
Methods: In this BAV registry report, we analyzed 354 patients who underwent 432
consecutive procedures (2005-2010) in a single referral center. Univariate and
multivariate logistic regression models were used to evaluate associations between
baseline characteristics, BIV vs. UFH use, VCD vs. manual compression use, and in-
hospital outcomes.
Results: The study cohort is divided in to four groups as shown in the figure. There
were a total of 47 (10.9%) bleeding complications in-hospital: 29 (6.7%) were major
and 18 (4.2%) were minor. The figure shows these results in the 4 groups. There were
no significant differences in the incidence of other vascular complications (group 1:
7.7%, group 2: 3.7%, group 3: 5.3% and group 4: 4.7%; p=0.91) among the four
groups. Among patients who received VCD, those who received UFH (group 2) had
higher mortality compared to those who received BIV (group 4) (8.9% vs. 3.8%,
HR=3.5, 95% CI: 1.2 to 10.2; p=0.025); Among patients treated with BIV, those who
did not receive VCD (group 3) had higher mortality compared to those who received
VCD (group 4) (14.9% vs. 3.8%, HR=4.8, 95% CI: 1.8-12.7; p=0.001).
In-hospital bleeding complications among the four groups.
Conclusion: The combined use of bivalirudin and the “preclosure” technique using
the suture-based VCD was associated with very low bleeding complications after BAV,
and a favorable mortality trend. Fully adjudicated data according to V-ARC and B-
ARC definitions will be presented.
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Background: High on-treatment platelet reactivity (HOPR) in patients on clopidogrel
is associated with adverse events following PCI. The impact of presentation with acute
coronary syndrome (ACS) upon platelet reactivity, however, is not well-understood.
Methods: Patients received 600 mg clopidogrel and 325 mg aspirin at the time of PCI
and underwent platelet reactivity testing with Vasodilator Stimulated Phosphoprotein
Phosphorylation (VASP) 6-24 hours after PCI. HOPR was defined as VASP platelet
reactivity index >50%. ACS was defined as ≥2 of the following: 1) symptoms
consistent with myocardial ischemia; 2) ST elevation or depression ≥1 mm in ≥2
contiguous leads on EKG; 3) cardiac troponin level above upper limit of normal. VASP
platelet reactivity index and HOPR were compared between groups using the Wilcoxon
and Chi-square tests, respectively. Multivariable logistic regression was used to assess
the independent effect of ACS upon HOPR.
Results: 377 patients were enrolled, of whom 12.9% presented with ACS. Patients
with ACS were less likely to have a history of CAD (22.4% v. 59.8%) or previous PCI
(12.5 v. 46.6%) and more likely to have a history of congestive heart failure (22.4%
vs. 11.6%) or a left anterior descending lesion (47.8% v. 30.2%; p <0.001 for all
comparisons). Median VASP platelet reactivity index was higher in ACS patients
(52.6% v. 38.3%, p=0.02), as was incidence of HOPR (55.1% v. 34.6%, p=0.007).
Following multivariable adjustment, ACS remained significantly associated with
HOPR (OR 2.18, 95% CI 1.15-4.12, p=0.02; Table).
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